HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
about
CIViC databaseHER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expressionThe emerging role of neoadjuvant chemotherapy for rectal cancerGenomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials.Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).High levels of serum platelet-derived growth factor-AA and human epidermal growth factor receptor-2 are predictors of colorectal cancer liver metastasisHER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory.Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin.Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.Noninvasive Biomarkers of Colorectal Cancer: Role in Diagnosis and Personalised Treatment Perspectives
P2860
Q27612411-3F9E1586-450B-4802-B8E3-44E47298D1FBQ33690070-35BD4182-9B6F-427C-A18A-58DA01C4F622Q34234935-DF69823E-90F9-408F-B6C1-E419B49360A1Q35079683-1567E6AB-BCBE-47D0-AF00-92293B53F2D1Q36671427-11449DB8-619D-4F62-9444-6A0F9FE5C006Q37109905-B373A3C5-4F97-4C08-8EBB-280B71088D19Q37662632-E4FC671F-E2FC-4CD1-A4BA-BD03B36B80CBQ37708897-7C56D4B9-08F0-46DB-AE80-694E39E83656Q38827897-432B08E3-8016-452B-8946-99B7670B091AQ42290643-F56EB768-C822-4D99-A070-4DE2A13CA1BDQ54962247-0124C8AE-EFD7-499B-8EDD-9259FF9B50A9Q57739115-A3E3FD84-1A45-47D5-A1E8-69441E36F862
P2860
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@ast
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@en
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@nl
type
label
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@ast
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@en
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@nl
prefLabel
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@ast
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@en
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@nl
P2093
P50
P921
P356
P1433
P1476
HER2 in high-risk rectal cance ...... RT) with or without cetuximab.
@en
P2093
A Cervantes
A Wotherspoon
D Gonzalez de Castro
F Sclafani
P304
P356
10.1093/ANNONC/MDT408
P577
2013-12-01T00:00:00Z